Clinical Trials
7 trialsNCT06462222 2026-05-11
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Guangzhou Medical University
Phase 1/2 Active not recruiting
NCT06462092 2025-09-29
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06762080 2025-05-20
Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06809517 2025-05-20
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06809530 2025-05-18
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2 Recruiting
NCT05289908 2025-05-04
Intrathecal Pemetrexed for Leptomeningeal Metastasis
The First Hospital of Jilin University
Phase 1/2 Completed
NCT03507244 2019-12-26
Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors
The First Hospital of Jilin University
Phase 1/2 Completed